drugset / Trial / NCT04398524
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
NaSingle-groupOpen-labelTreatment
Summary
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2024-06-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | — |
| Subject | PELTOPEPIMUT-S | Vaccine | — | — |